22nd Century Group, a leader in tobacco harm reduction, has entered into a new cannabis research collaboration with Anandia Laboratories.
As a part of this research collaboration, Vancouver, Canada-based Anandia Laboratories will develop and grow cannabis strains that express highly desirable characteristics and will lead to potential commercialization opportunities. The initial focus of the collaboration will include cannabinoid-free cannabis for the commercial hemp industry and high levels of non-THC cannabinoids, such as CBD, for legal medical marijuana markets.
Dr. Paul Rushton, 22nd Century’s new vice president of plant biotechnology, will have responsibility for the company’s partnership with Anandia Laboratories.
Smoking tobacco and/or smoking tobacco mixed with cannabis might lead to worse physical health outcomes than smoking cannabis on its own, according to a San Francisco Chronicle blog quoting an Australian study.
Researchers at the University of New South Wales, Sydney, Australia, recruited 350 adults over the age of 40 and divided them into four groups: cannabis-only users, tobacco+cannabis users, tobacco-only users, and a control group of abstainers.
The population size was small, but the authors concluded in a report published in the journal Addictive Behaviors that the control and cannabis-only groups tended to report the best health, while the two tobacco-smoking groups fared the worst.
All three smoking groups reported significantly higher rates of emphysema than did the control group. But all members of the cannabis-only group diagnosed with the debilitating lung disease had formerly been regular tobacco smokers.